Eli Lilly and Walmart have partnered to offer in-store pickup of Zepbound (tirzepatide) single-dose vials through the LillyDirect platform by mid-November.
The collaboration marks the first time patients using LillyDirect, the company’s direct-to-consumer healthcare platform, will be able to access self-pay pricing for Zepbound vials at a retail pharmacy, according to an Oct. 29 news release.
LillyDirect’s self-pay pricing offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medications for obesity, with pricing ranging from $349 per month for the recommended 2.5 mg starting dose to $499 for all other strengths through the Zepbound Self Pay Journey Program.
The Zepbound vials will be available to patients with a valid, on-label prescription, regardless of insurance status, the release said.
In the second quarter of 2025, approximately 35% of new Zepbound prescriptions were filled through LillyDirect’s self-pay option. The company said it plans to expand access to its medicines through additional direct-to-consumer channels.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.